Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Arranta Bio
Sort By
Newest First
1 / 2
1 / 2
CDMO Acquisition
Recipharm Acquires Arranta Bio, a CDMO Leader in Advanced Therapy Medicinal Products (ATMPs), to Expand its Biologics Offering in the U.S.
Recipharm AB
PR-M02-22-17
Feb 18, 2022
mRNA Vaccine Manufacturing
Presenting an Integrated Solution for mRNA Vaccine Manufacturing
Mark Bamforth; Dave Stevens
Arranta Bio
PAO-01-22-R250-04
Jan 26, 2022
mRNA Manufacturing
Serving an Accelerated Market with mRNA Production
Mark Bamforth
Arranta Bio
PAO-11-21-CL-06
Dec 08, 2021
Investing in mRNA Production
Michael Wourms
Arranta Bio
PA766
Nov 22, 2021
mRNA Manufacturing
Limiting Risk In mRNA Development and Production
Doug Kennedy
Arranta Bio
PAO-11-21-CL-05
Nov 22, 2021
mRNA Manufacturing
Integrating a Fragmented mRNA Supply Chain
Dave Stevens
Arranta Bio
PAO-11-21-CL-04
Nov 22, 2021
Sale
Arranta Bio Announces Completion of Sale of Florida Site and Progress on $150M Investment Plan to Expand Development and Commercial Manufacturing Services
Arranta Bio
PA775
Nov 16, 2021
mRNA
Integrated Support Facilitates mRNA Product Development and Commercialization
Michael Wourms; Dave Stevens
Arranta Bio
PAO-10-21-CL-15
Oct 26, 2021
Live Biotherapeutic Products
Enabling the Commercialization of Microbiome Live Biotherapeutic Products with Fit-for-Purpose Cryopreservatives
Aaron B. Cowley, Ph.D.; Nicole O'Brien, Ph.D.
Arranta Bio
PAO-09-21-CL-11
Sep 28, 2021
mRNA Vaccines
Arranta Bio Announces First End-to-End Manufacturing for mRNA Vaccines in its Commercial-Ready GMP Facility
Arranta Bio
PR-M09-21-05
Sep 23, 2021
Live Biotherapeutic Products
Design Considerations for Live Biotherapeutic Product Facilities Working with Spore-Forming Bacteria
Aaron B. Cowley, Ph.D.; Judith Bodette; Brian Duffy
Arranta Bio
PAO-06-21-CL-10
Jun 25, 2021
Live Biotherapeutic Products
Framing the Narrative on CMC Development for Microbiome Therapeutics
Aaron B. Cowley, Ph.D.; Melanie Cerullo; Jeff Heiser
Arranta Bio
PAO-06-21-CL-05
Jun 14, 2021
Manufacturing Facility
Arranta Bio Announces Addition of 130,000 sq. ft. Boxborough, Mass., Manufacturing Facility to Supply Clinical and Commercial Microbiome Products for Clients and Closes Series B Equity Financing
Arranta Bio
PR-M03-21-002-1066
Mar 08, 2021
The Road to 2021
Road to 2021 Day 3: Scotland & England
Nigel Walker
Nice Insight
PAO-04-22-R221-30
Jan 01, 2021
Corporate Social Responsibility
Life Imitating Science: Arranta Bio’s Commitment to Corporate Social Responsibility and Diversity
Susan Surabian; Melanie Cerullo
Arranta Bio
PAP-Q4-20-CL-002
Dec 09, 2020
The Future of Healthcare
How Does Arranta Bio Envision the Future of the Pharma/Biopharma Industry?
Arranta Bio
PAP-Q4-20-RT2-007
Dec 09, 2020
Microbiome CDMO
Extensive Experience Is Crucial to Speed to the Clinic and Market for Live Biotherapeutic Products
Aaron B. Cowley, Ph.D.
Arranta Bio
PAP-Q3-20-CL-004
Sep 29, 2020
Design Logic
Experience to Solve Your Microbiome Challenges
Nice Insight
PAP-Q3-20-NI-010
Sep 29, 2020
The Future of Healthcare
How Is Arranta Bio Evolving its Business Model to Meet the Future of Healthcare?
Arranta Bio
PAP-Q3-20-RT2-009
Sep 29, 2020
Capacity Expansion
Arranta Bio Announces Mechanical Completion of Commercial-Ready Capacity for Advanced Biologics
Arranta Bio
PR-M09-20-30
Sep 28, 2020
